SLC22A3

Across TCGA pan-cancer cohorts, SLC22A3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SLC22A3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SLC22A3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC22A3 is over-expressed in tumor, although a few such as KICH and BLCA show the opposite, repressed pattern.

COAD, KICH, and BLCA are the cancer types where SLC22A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC22A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+1.814	<.001	12	view →
KICH	All	IV	−3.215	<.001	11	view →
BLCA	Male	IV	−3.055	<.001	11	view →
LUAD	Male	III,IV	−3.163	<.001	10	view →
THCA	Male	All	−0.948	<.001	8	view →
LUSC	Male	II,III,IV	−2.808	<.001	7	view →
READ	All	All	+1.576	<.001	7	view →
KIRC	Male	All	−0.924	<.001	7	view →
UCEC	All	III,IV	−4.949	<.001	6	view →
BRCA	All	III,IV	−2.025	<.001	6	view →
KIRP	All	III,IV	−1.023	.003	5	view →
HNSC	Male	IV	−1.598	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SLC22A3–COAD

Open the COAD breakdown →